| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.8 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.8 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.8 |